Search

Your search keyword '"Padma-Nathan, Harin"' showing total 211 results
Start Over Author "Padma-Nathan, Harin"
211 results on '"Padma-Nathan, Harin"'

14. Oral sildenafil in the treatment of erectile dysfunction

Author

Goldstein, Irwin, Lue, Tom F., Padma-Nathan, Harin, Rosen, Raymond C., Steers, William D., and Wicker, Pierre A.

Subjects
Viagra (Medication) -- Evaluation, Impotence -- Drug therapy, Sildenafil -- Evaluation
Abstract

The drug sildenafil (Viagra) may be effective in treating erectile dysfunction in men. The drug inhibits the breakdown of cyclic GMP, a naturally occurring chemical in the body that promotes penile erection. Researchers randomly assigned 225 men to take sildenafil or placebo for 32 weeks. They were started on 50 milligrams of the drug and the dose could be increased or decreased. Sixty-nine percent of the attempts at intercourse were successful in men taking the drug, compared to 22% of attempts in men taking placebo. Side effects were minimal and occurred in less than 20% of the men.

Published
1998

15. Treatment of men with erectile dysfunction with transurethral alprostadil

Author

Padma-Nathan, Harin, Hellstrom, Wayne J.G., Kaiser, Fran E., Labasky, Richard F., Lue, Tom F., Nolten, Wolfram E., Norwood, Paul C., Peterson, Craig A., Shabsigh, Ridwan, Tam, Peter Y., Place, Virgil A., and Gesundheit, Neil

Subjects
Impotence -- Drug therapy, Synthetic prostaglandins E -- Evaluation
Abstract

Injecting alprostadil directly into the urethra before intercourse appears to be successful in treating male impotence. Alprostadil is a synthetic form of prostaglandin E1. Researchers tested the treatment on 1,511 men and then taught the men how to administer the drug at home. The device consists of an applicator with a small thin stem that injects the drug into the urethra when a button is depressed. Approximately 65% of the men sustained erections sufficient for intercourse after the treatment, compared to 19% who injected a placebo. Ten percent of the men experienced mild penile pain after the injection.

Published
1997

18. Pharmacotherapy for Erectile Dysfunction

Author

Padma‐Nathan, Harin, Christ, George, Adaikan, Ganesan, Becher, Edgardo, Brock, Gerald, Carrier, Serge, Carson, Culley, Corbin, Jackie, Francis, Sharon, DeBusk, Robert, Eardley, Ian, Hedlund, Hans, Hutter, Adolph, Jackson, Graham, Kloner, Robert, Lin, Shin, McVary, Kevin, McCullough, Andrew, Nehra, Ajay, Porst, Hartmut, Schulman, Claude, Seftel, Allen, Sharlip, Ira, Stief, Christian, and Teloken, Claude

Published
2004
Full Text
View/download PDF

20. Summary of the Recommendations on Sexual Dysfunctions in Men

Author

Lue, Tom F., Giuliano, François, Montorsi, Francesco, Rosen, Raymond C., Andersson, Karl Erik, Althof, Stanley, Christ, George, Hatzichristou, Dimitrios, Hirsch, Mark, Kimoto, Yasasuke, Lewis, Ronald, McKenna, Kevin, MacMahon, Chris, Morales, Alvaro, Mulcahy, John, Padma Nathan, Harin, Pryor, John, De Tejada, Inigo Saenz, Shabsigh, Ridwan, and Wagner, Gorm

Published
2004
Full Text
View/download PDF

28. REPORT OF THE INTERNATIONAL CONSENSUS DEVELOPMENT CONFERENCE ON FEMALE SEXUAL DYSFUNCTION: DEFINITIONS AND CLASSIFICATIONS

Author

BASSON, ROSEMARY, BERMAN, JENNIFER, BURNETT, ARTHUR, DEROGATIS, LEONARD, FERGUSON, DAVID, FOURCROY, JEAN, GOLDSTEIN, IRWIN, GRAZIOTTIN, ALESSANDRA, HEIMAN, JULIA, LAAN, ELLEN, LEIBLUM, SANDRA, PADMA-NATHAN, HARIN, ROSEN, RAYMOND, SEGRAVES, KATHLEEN, SEGRAVES, R. TAYLOR, SHABSIGH, RIDWAN, SIPSKI, MARCALEE, WAGNER, GORM, and WHIPPLE, BEVERLY

Published
2000
Full Text
View/download PDF

33. PDE-5 Inhibitor Therapy for Erectile Dysfunction Secondary to Nerve-Sparing Radical Retropubic Prostatectomy

Author

Padma-Nathan, Harin

Subjects
Post-Radical Prostatectomy Erectile Dysfunction
Abstract

The majority of patients receiving therapy for erectile dysfunction (ED) following post-radical retropubic prostatectomy (RRP) are treated with phosphodiesterase (PDE)-5 inhibitors, which seem to have variable efficacy in this population. So far, the only head-to-head trials with PDE-5 inhibitors have been in general ED patients and not in post-RRP patients. Both vardenafil and tadalafil failed to meet statistical noninferiority to sildenafil in head-to-head trials. To date, only sildenafil has demonstrated efficacy in the prevention of post-nerve-sparing RRP ED. The selection of a PDE-5 inhibitor requires consideration of the patient's sexual activity pattern as well as the drug's efficacy and its ability to meet the patient's expectations. In this regard, sildenafil continues to account for almost 70% of PDE-5 inhibitor prescriptions in the United States.

Published
2005

43. Roundtable discussion: tadalafil study group

Author

Kloner, Robert A, primary, Brindis, Ralph G, additional, Cheitlin, Melvin D, additional, Kuritzky, Louis, additional, Miller, Thomas A, additional, Padma-Nathan, Harin, additional, and Rosen, Raymond C, additional

Published
2003
Full Text
View/download PDF

50. Sildenafil Citrate, the Classic PDE5 Inhibitor.

Author

Klein, Eric A., Broderick, Gregory A., and Padma-Nathan, Harin

Abstract

In 1988, a new class of drugs was heralded by the release of sildenafil citrate, an orally administered, potent, and selective phosphodiesterase type 5 (PDE5) inhibitor. [ABSTRACT FROM AUTHOR]

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results